Neoplasm

DYN’R Medical Systems and Mevion announce the launch of the SDX® Respiratory Gating System synchronized interface with MEVION S250i and the completion of the installation at OU Health.

Thursday, October 21, 2021 - 5:00pm

DYNR Medical Systems and Mevion Medical Systems, the leader in compact proton therapy, are delighted to announce the launch of a new gating option for their joint customers.

Key Points: 
  • DYNR Medical Systems and Mevion Medical Systems, the leader in compact proton therapy, are delighted to announce the launch of a new gating option for their joint customers.
  • The SDX System is the most effective proton therapy respiratory monitoring solution, especially during the lung, breast and liver treatments.
  • The development of the synchronized interface with MEVION S250i was an important target of our business development plan said Francois Galzin, President & CEO of DYNR Medical Systems.
  • Since 2004, Mevion Medical Systems has been the leading provider of compact proton therapy systems for cancer care.

Longbow Immunotherapy Launches ReACT, A Novel CAR-T Platform Targeting Solid Tumors

Thursday, October 21, 2021 - 2:00pm

Longbow Immunotherapy, a newly formed biotech advancing solid tumor therapy, announced its formation and exclusive license of the ReACT platform from the Versiti Blood Research Institute.

Key Points: 
  • Longbow Immunotherapy, a newly formed biotech advancing solid tumor therapy, announced its formation and exclusive license of the ReACT platform from the Versiti Blood Research Institute.
  • ReACT (Re-energized adoptive cell transfer), combines CAR-T cell therapy with microbial immunotherapies, such as bacteria and oncolytic viruses, to synergistically treat solid tumors.
  • Its advantages include modification of the tumor microenvironment, localized activity, broad targeting of tumor antigens, and prevention of T cell exhaustion.
  • Longbow also plans to extend the application of ReACT beyond initial bladder cancer uses, as ReACT T cells can be engineered to recognize and synergize with any bacterial immunotherapy or oncolytic virus targeting solid tumors.

RefleXion Highlights New Cancer Treatment Research at ASTRO 2021

Thursday, October 21, 2021 - 3:00pm

The company will showcase technology from the RefleXion X1 machine in its booth, #1309.

Key Points: 
  • The company will showcase technology from the RefleXion X1 machine in its booth, #1309.
  • (Oral Abstract, Room 178 a/b)
    40 Physical validation of biology-guided radiotherapy for delivering a tracked dose distribution to a moving PET-avid target.
  • (Oral Abstract, Room 184 a/b/c/d)
    1:30 PM 98 Radiation and Cancer Physics Evaluation of PSMA-PET biology-guided radiotherapy sequential boost to the dominant intraprostatic lesion in low-volume advanced prostate cancer.
  • Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT).

Philips brings clarity to every moment of cancer care with new patient-centered innovations at ASTRO 2021

Thursday, October 21, 2021 - 2:00pm

Philips will also highlight its deepened strategic partnership with Elekta to support the ambition of providing clear care pathways and predictable outcomes for every cancer patient.

Key Points: 
  • Philips will also highlight its deepened strategic partnership with Elekta to support the ambition of providing clear care pathways and predictable outcomes for every cancer patient.
  • Today, cancer care is a long, complex journey through various stages, settings, and providers, putting a significant burden on both patients and clinicians.
  • The number of new cancer cases is expected to rise by about 70% over the next two decades [1].
  • At this years ASTRO meeting were highlighting how were connecting clinical and operational teams with the information they need to optimize and personalize cancer care.

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Thursday, October 21, 2021 - 1:31pm

Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.
  • 1 Together with cancers of the gastroesophageal junction, they constitute an important and growing global health concern.
  • PD-L1 is a critical biomarker for response to anti-PD-1 therapies, including the immunotherapeutic agent OPDIVO (nivolumab).
  • CA: A Cancer Journal for Clinicians, 71(3), 209249. https://doi.org/10.3322/caac.21660
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005619/en/

Artiva Biotherapeutics to Present Preclinical Data for AB-201, a HER2-Targeting CAR-NK Cell Therapy, at SITC 36th Annual Meeting

Thursday, October 21, 2021 - 2:00pm

The full abstract is scheduled to be available on the SITC website on November 9, 2021.

Key Points: 
  • The full abstract is scheduled to be available on the SITC website on November 9, 2021.
  • HER2 is a receptor tyrosine kinase that is overexpressed on many solid tumors, including breast, gastric, and bladder cancers.
  • AB-201 is an allogeneic anti-HER2 CAR-NK cell therapy candidate manufactured from cord blood, containing a proprietary HER2 antigen recognition domain.
  • Artiva is developing AB-201 for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers.

Imvax to Present Preclinical Data on IGV-001 Mechanism of Action at SITC Annual Meeting

Thursday, October 21, 2021 - 1:00pm

The poster highlights recent preclinical data for the companys most advanced product candidate, IGV-001.

Key Points: 
  • The poster highlights recent preclinical data for the companys most advanced product candidate, IGV-001.
  • The data elucidate potential mechanisms for the observed immune-stimulating and tumor-suppressing activity of IGV-001 seen in the Phase 1 clinical study for glioblastoma.
  • Were pleased to share new insights into the mechanism of action of IGV-001, which are supportive of the clinical efficacy data weve previously reported, said John Furey, Chief Executive Officer.
  • Imvaxs portfolio includes several programs designed to stimulate a patients immune system against the entire antigen signature of their tumor.

Exacis Biotherapeutics Announces Strategic Partnership With CCRM For Specialty Manufacturing Of Services And Investment For Development Of iPSC-Derived mRNA-Engineered NK Cells

Thursday, October 21, 2021 - 1:00pm

The partnership also includes a cashinvestmentinto Exacisby CCRM Enterprises Holdings Ltd., the for-profit venture investment arm of CCRM,whichwill be used to fund operations.

Key Points: 
  • The partnership also includes a cashinvestmentinto Exacisby CCRM Enterprises Holdings Ltd., the for-profit venture investment arm of CCRM,whichwill be used to fund operations.
  • CCRM is a recognized leader in iPSC-derived cell therapy development and manufacturing and we are thrilled to have them as a partner.
  • Their confidence in Exacis is evidenced by the accompanying investment, by CCRM Enterprises Holdings Ltd., underscoring the unique value proposition offered by Exacis' differentiated platform and approach to cell therapies.
  • T and NK cells are types of human immune cells that are ableto recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.

Atreca Enters into Licensing Agreement with Bill & Melinda Gates Medical Research Institute to Develop a Monoclonal Antibody for the Prevention of Malaria   

Thursday, October 21, 2021 - 1:00pm

MAM01/ATRC-501 is an engineered version of a human monoclonal antibody generated following vaccination with Mosquirix and identified via Atrecas discovery platform.

Key Points: 
  • MAM01/ATRC-501 is an engineered version of a human monoclonal antibody generated following vaccination with Mosquirix and identified via Atrecas discovery platform.
  • Gates MRI plans to undertake development efforts for MAM01/ATRC-501 for prevention of malaria in infant and pediatric populations in malaria endemic regions.
  • Potential product development opportunities for Atreca include prevention of malaria for those traveling to regions where malaria may be circulating.
  • Tackling the public health challenges posed by malaria is a priority for our Institute, said Emilio Emini Ph.D., CEO of the Bill & Melinda Gates Medical Research Institute.

VYNE Therapeutics Announces Formation of Scientific Advisory Board

Thursday, October 21, 2021 - 1:00pm

BRIDGEWATER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the formation of its Scientific Advisory Board (SAB) composed of leading scientists and clinicians specializing in immunological and inflammatory diseases.

Key Points: 
  • BRIDGEWATER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced the formation of its Scientific Advisory Board (SAB) composed of leading scientists and clinicians specializing in immunological and inflammatory diseases.
  • The SAB will provide scientific expertise and guidance to the VYNE management team and Board as the Company progresses its pipeline of innovative treatments for immuno-inflammatory conditions.
  • Iain Stuart, Chief Scientific Officer at VYNE, said The SABs immediate focus is our recently licensed BET inhibitor platform.
  • For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter.